Expression of protein kinase CK2 in astroglial cells of normal and neovascularized retina

American Journal of Pathology

Volumn 168, Issue 5, 2006, Pages 1722-1736

  Kramerov, Andrei A ^a,g   Saghizadeh, Mehrnoosh ^a   Pan, Hao ^b   Kabosova, Andrea ^a   Montenarh, Mathias ^f   Ahmed, Khalil ^c   Penn, John S ^d   Chan, Candy K ^e   Hinton, David R ^e   Grant, Maria B ^b   Ljubimov, Alexander V ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f SAARLAND UNIVERSITY   (Germany)

^g BURNS AND ALLEN RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4,5,6,7 TETRABROMOBENZOTRIAZOLE; BENZOTRIAZOLE DERIVATIVE; CASEIN KINASE II; EMODIN; MESSENGER RNA; OCTREOTIDE; PROTEIN KINASE INHIBITOR; SCR 011; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; ASTROCYTE; CONTROLLED STUDY; ENZYME SUBUNIT; EYE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RETINA NEOVASCULARIZATION; RETINOPATHY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 33646508546     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2006.050533     Document Type: Article

References (81)

1. Fruttiger M: Development of the mouse retinal vasculature: angiogenesis versus vasculogenesis. Invest Ophthalmoi Vis Sci 2002, 43:522-527
2. McLeod DS, Crone SN, Lutty GA: Vasoproliferation in the neonatal dog model of oxygen-induced retinopathy, Invest Ophthalmol Vis Sci 1996, 37:1322-1333
3. Gariano RF: Cellular mechanisms in retinal vascular development. Prog Retin Eye Res 2003, 22:295-306
4. Grant MB, May WS, Caballero S, Brown GA, Guthrie SM, Mames RN, Byrne BJ, Vaught T, Spoerri PE, Peck AB, Scott EW: Adult hematopoietic stem cells provide functional hemangioblast activity during retinal neovascularization. Nat Med 2002, 8:607-612
5. Sengupta N, Caballero S, Mames RN, Timmers AM, Saban D, Grant MB: Preventing stem cell incorporation into choroidal neovascularization by targeting homing and attachment factors. Invest Ophthalmol Vis Sci 2005, 46:343-348
6. Otani A, Kinder K, Ewalt K, Otero FJ, Schimmel P, Friedlander M: Bone marrow-derived stem cells target retinal astrocytes and can promote or inhibit retinal angiogenesis. Nat Med 2002, 8:1004-1010
7. Grant MB, Afzal A, Spoerri P, Pan H, Shaw LC, Mames RN: The role of growth factors in the pathogenesis of diabetic retinopathy. Expert Opin Investig Drugs 2004, 13:1275-1293
8. Saint-Geniez M, D'Amore PA: Development and pathology of the hyaloid, choroidal and retinal vasculature. Int J Dev Biol 2004, 48:1045-1058
9. Thurston G, Gale NW: Vascular endothelial growth factor and other signaling pathways in developmental and pathologic angiogenesis. Int J Hematol 2004, 80:7-20
10. Bikfalvi A: Platelet factor 4: an inhibitor of angiogenesis. Semin Thromb Hemost 2004, 30:379-385
11. Eichler W, Yafai Y, Keller T, Wiedemann P, Reichenbach A: PEDF derived from glial Müller cells: a possible regulator of retinal angiogenesis. Exp Cell Res 2004, 299:68-78
12. Frank RN: Diabetic retinopathy. N Engl J Med 2004, 350:48-58
13. Fong DS, Aiello LP, Ferris III FL, Klein R: Diabetic retinopathy. Diabetes Care 2004, 27:2540-2553
14. Cai J, Boulton M: The pathogenesis of diabetic retinopathy: old concepts and new questions. Eye 2002, 16:242-260
15. Caldwell RB, Bartoli M, Behzadian MA, EI-Remessy AE, Al-Shabrawey M, Platt DH, Caldwell RW: Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev 2003, 19:442-455
16. Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E: Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995, 1:1024-1028
17. Leske DA, Wu J, Fautsch MP, Karger RA, Berdahl JP, Lanier WL, Holmes JM: The role of VEGF and IGF-1 in a hypercarbic oxygen-induced retinopathy rat model of ROP. Mol Vis 2004, 10:43-50
18. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE: Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA 1995, 92:905-909
19. Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, Jeltsch M, Mitchell C, Alitalo K, Shima D, Betsholtz C: VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 2003, 161:1163-1177
20. Campochiaro PA: Retinal and choroidal neovascularization. J Cell Physiol 2000, 184:301-310
21. Mi H, Haeberle H, Barres BA: Induction of astrocyte differentiation by endothelial cells. J Neurosc 2001, 21:1538-1547
22. Yamada H, Yamada E, Ando A, Seo MS, Esumi N, Okamoto N, Vinores M, LaRochelle W, Zack DJ, Campochiaro PA: Platelet-derived growth factor-A-induced retinal gliosis protects against ischemic retinopathy. Am J Pathol 2000, 156:477-487
23. Litchfield DW: Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem J 2003, 369:1-15
24. Pinna LA: The raison d'être of constitutively active protein kinases: the lesson of CK2. Ace Chem Res 2003, 36:378-384
25. Unger GM, Davis AT, Slaton JW, Ahmed K: Protein kinase CK2 as regulator of cell survival: implications for cancer therapy. Curr Cancer Drug Targets 2004, 4:77-84
26. Olsten ME, Litchfield DW: Order or chaos? An evaluation of the regulation of protein kinase CK2. Biochem Cell Biol 2004, 82:681-693
27. Ljubimov AV, Caballero S, Aoki A, Grant MB, Castellon R: Involvement of protein kinase CK2 in angiogenesis and retinal neovascularization. Invest Ophthalmol Vis Sci 2004, 45:4583-4591
28. Goueli SA, Davis AT, Arfman E, Vessella R, Ahmed K: Monoclonal antibodies against nuclear casein kinase NII (PK-N2). Hybridoma 1990, 9:609-618
29. Faust M, Jung M, Gunther J, Zimmermann R, Montenarh M: Localization of individual subunits of protein kinase CK2 to the endoplasmic reticulum and to the Golgi apparatus. Mol Cell Biochem 2001, 227:73-80
30. Engvall E, Davis GE, Dickerson K, Ruoslahti E, Varan S, Manthorpe M: Mapping of domains in human laminin using monoclonal antibodies: localization of the neurite-promoting site. J Cell Biol 1986, 103:2457-2465
31. Couchman JR, Ljubimov AV: Mammalian tissue distribution of a large heparan sulfate proteoglycan detected by monoclonal antibodies. Matrix 1989, 9:311-321
32. Nastainczyk W, Issinger OG, Guerra B: Epitope analysis of the MAb 1AD9 antibody detection site in human protein kinase CK2α-subunit. Hybrid Hybridomics 2003, 22:87-90
33. Kobayashi S, Vidal I, Pena JD, Hernandez MR: Expression of neural cell adhesion molecule (NCAM) characterizes a subpopulation of type 1 astrocytes in human optic nerve head. Glia 1997, 20:262-273
34. Saghizadeh M, Kramerov AA, Tajbakhsh J, Aoki AM, Wang C, Chai NN, Ljubimova JY, Sasaki T, Sosne G, Carlson MR, Nelson SF, Ljubimov AV: Proteinase and growth factor alterations revealed by gene microarray analysis of human diabetic corneas. Invest Ophthalmol Vis Sci 2005, 46:3604-3615
35. Penn JS, Henry MM, Tolman BL: Exposure to alternating hypoxia and hyperoxia causes severe proliferative retinopathy in the newborn rat. Pediatr Res 1994, 36:724-731
36. 2 variation determines the severity of oxygen-induced retinopathy in newborn rats. Invest Ophthalmol Vis Sci 1995, 36:2063-2070
37. Smith LE, Wesolowski E, McLellan A, Kostyk SK, D'Amato R, Sullivan R, D'Amore PA: Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 1994, 35:101-111
38. Grant MB, Caballero S, Marnes RN, Shapiro G: Designer drugs: peptidomimetics of somatostatin specifically target ocular neovascularization. Annual Meeting Abstract and Program Planner. Assoc Res Vis Ophthalmol 2005, Abstract 4171
39. Ghosh F, Gjorloff K: Protein kinase C expression in the rabbit retina after laser photocoagulation. Graefes Arch Clin Exp Ophthalmol 2005, 243:803-810
40. Abu-El-Asrar AM, Dralands L, Missotten L, Al-Jadaan IA, Geboes K: Expression of apoptosis markers in the retinas of human subjects with diabetes. Invest Ophthalmol Vis Sci 2004, 45:2760-2766
41. Mizutani M, Gerhardinger C, Lorenzi M: Muller cell changes in human diabetic retinopathy. Diabetes 1998, 47:445-449
42. Salvador-Silva M, Aoi S, Parker A, Yang P, Pecen P, Hernandez MR: Responses and signaling pathways in human optic nerve head astrocytes exposed to hydrostatic pressure in vitro. Glia 2004, 45:364-377
43. Mammalian Gene Collection Program Team: Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proc Natl Acad Sci USA 2002, 99:16899-16903
44. Chan-Ling T, Page MP, Gardiner T, Baxter L, Rosinova E, Hughes S: Desmin ensheathment ratio as an indicator of vessel stability: evidence in normal development and in retinopathy of prematurity. Am J Pathol 2004, 165:1301-1313
45. Lieth E, Barber AJ, Xu B, Dice C, Ratz MJ, Tanase D, Strother JM: Glial reactivity and impaired glutamate metabolism in short-term experimental diabetic retinopathy. Penn State Retina Research Group. Diabetes 1998, 47:815-820
46. Rungger-Brandle E, Dosso AA, Leuenberger PM: Glial reactivity, an early feature of diabetic retinopathy. Invest Ophthalmol Vis Sci 2000. 41:1971-1980
47. Janosch P, Kieser A, Eulitz M, Lovric J, Sauer G, Reichert M, Gounari F, Buscher D, Baccarini M, Mischak H, Kolch W: The Raf-1 kinase associates with vimentin kinases and regulates the structure of vimentin filaments. FASEB J 2000, 14:2008-2021
48. Ulloa L, Ibarrola N, Avila J, Diez-Guerra FJ: Microtubule-associated protein 1B (MAP1B) is present in glial cells phosphorylated different than in neurones. Glia 1994, 10:266-275
49. Wirkner U, Voss H, Ansorge W, Pyerin W: Genomic organization and promoter identification of the human protein kinase CK2 catalytic subunit α (CSNK2A1). Genomics 1998, 48:71-78
50. Lozeman FJ, Litchfield DW, Piening C, Takio K, Walsh KA, Krebs EG: Isolation and characterization of human cDNA clones encoding the α and the α′ subunits ot casein kinase II. Biochemistry 1990, 29:8436-8447
51. Pyerin W, Ackermann K: Transcriptional coordination of the genes encoding catalytic (CK2α) and regulatory (CK2α) subunits of human protein kinase CK2. Mol Cell Biochem 2001, 227:45-57
52. Pyerin W, Ackermann K: The genes encoding human protein kinase CK2 and their functional links. Prog Nucl Acid Res Mol Biol 2003, 74:239-273
53. Hilgard P, Huang T, Wolkoff AW, Stockert RJ: Translated Alu sequence determines nuclear localization of a novel catalytic subunit of casein kinase 2. Am J Physiol 2002, 283:C472-C483
54. Barber AJ, Antonetti DA, Gardner TW: Altered expression of retinal occludin and glial fibrillary acidic protein in experimental diabetes. The Penn State Retina Research Group. Invest Ophthalmol Vis Sci 2000, 41:3561-3568
55. Simpson DA, Feeney S, Boyle C, Stitt AW: Retinal VEGF mRNA measured by SYBR green I fluorescence: a versatile approach to quantitative PCR. Mol Vis 2000, 6:178-183
56. Smith LE, Kopchick JJ, Chen W, Knapp J, Kinose F, Daley D, Foley E, Smith RG, Schaeffer JM: Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 1997, 276:1706-1709
57. McColm JR, Geisen P, Hartnett ME: VEGF isoforms and their expression after a single episode of hypoxia or repeated fluctuations between hyperoxia and hypoxia: relevance to clinical ROP. Mol Vis 2004, 10:512-520
58. Gu X, Samuel S, El-Shabrawey M, Caldwell RB, Barioli M, Marcus DM, Brooks SE: Effects of sustained hyperoxia on revascularization in experimental retinopathy of prematurity. Invest Ophthalmol Vis Sci 2002, 43:496-502
59. McLeod DS, D'Anna SA, Lutty GA: Clinical and histopathologic features of canine oxygen-induced proliferative retinopathy. Invest Ophthalmol Vis Sci 1998, 39:1918-1932
60. Zhang Y, Stone J: Role of astrocytes in the control of developing retinal vessels. Invest Ophthalmol Vis Sci 1997, 38:1653-1666
61. McLeod DS, Merges C, Fukushima A, Goldberg MF, Lutty GA: Histopathologic features of neovascularization in sickle cell retinopathy. Am J Ophthalmol 1997, 124:455-472
62. Feindt J, Mentlein R, Krisch B: Time-dependent influence of the somatostatin analogue octreotide on the proliferation of rat astrocytes and glioma cells. Brain Res 1997, 746:309-313
63. Grant MB, Mames RN, Fitzgerald C, Hazariwala KM, Cooper-DeHoff R, Caballero S, Estes KS: The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care 2000, 23:504-509
64. Chan-Ling T, Stone J: Degeneration of astrocytes in feline retinopathy of prematurity causes failure of the blood-retinal barrier. Invest Ophthalmol Vis Sci 1992, 33:2148-2159
65. Ahmad KA, Wang G, Slaton J, Unger G, Ahmed K: Targeting CK2 for cancer therapy. Anticancer Drugs 2005, 16:1037-1043
66. Pinna LA: Protein kinase CK2: a challenge to canons. J Cell Sci 2002, 115:3873-3878
67. Barnstable CJ, Tombran-Tink J: Neuroprotective and antiangiogenic actions of PEDF in the eye: molecular targets and therapeutic potential. Prog Retin Eye Res 2004, 23:561-577
68. Maik-Rachline G, Shaltiel S, Seger R: Extracellular phosphorylation converts pigment epithelium-derived factor from a neurotrophic to an antiangiogenic factor. Blood 2005, 105:670-678
69. Haskell CM (Ed): Cancer Treatment, ed 5. W.B. Saunders Company, Philadelphia, 2001, pp 62-86
70. Habtemariam T, Yu P, Oryang D, Nganwa D, Ayanwale O, Tameru B, Abdelrahman H, Ahmad A, Robnett V: Modelling viral and CD4 cellular population dynamics in HIV: approaches to evaluate intervention strategies. Cell Mol Biol 2001, 47:1201-1208
71. Folkman J: Endogenous angiogenesis inhibitors. APMIS 2004, 112:496-507
72. van Wijngaarden P, Coster DJ, Williams KA: Inhibitors of ocular neovascularization: promises and potential problems. JAMA 2005, 293:1509-1513
73. Speicher MA, Danis RP, Criswell M, Pratt L: Pharmacologic therapy for diabetic retinopathy. Expert Opin Emerg Drugs 2003, 8:239-250
74. Ziehe M, Donnini S, Morbidelli L: Development of new drugs in angiogenesis. Curr Drug Targets 2004, 5:485-493
75. Higgins RD, Yan Y, Schrier BK: Somatostatin analogs inhibit neonatal retinal neovascularization. Exp Eye Res 2002, 74:553-559
76. Grant MB, Caballero S: Somatostatin analogues as drug therapies for retinopathies. Drugs Today (Barc) 2002, 38:783-791
77. Ambler GR, Butler AA, Padmanabhan J, Breier BH, Gluckman PD: The effects of octreotide on GH receptor and IGF-I expression in the GH-deficient rat. J Endocrinol 1996, 149:223-231
78. Gargiulo P, Glusti C, Pietrobono D, La Torre D, Diacono D, Tamburrano G: Diabetes mellitus and retinopathy. Dig Liver Dis 2004, 36(Suppl 1):S101-S105
79. Lahlou H, Guillermet J, Hortala M, Vernejoul F, Pyronnet S, Bousquet C, Susini C: Molecular signaling of Somatostatin receptors. Ann NY Acad Sci 2004, 1014:121-131
80. Zhao B, Zhao H, Zhao N, Zhu XG: Cholangiocarcinoma cells express Somatostatin receptor subtype 2 and respond to octreotide treatment. J Hepatobiliary Pancreat Surg 2002, 9:497-502
81. Mottet D, Ruys SP, Demazy C, Raes M, Michiels C: Role for casein kinase 2 in the regulation of HIF-1 activity. Int J Cancer 2005, 117:764-774